Hospital

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses the stigma around drug diversion and the best ways to address and fight that stigma.

A P79S ORF2 variant demonstrates reduced RNA copy numbers released in the supernatant and impaired the production of infectious disease particles, investigators said.

Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.

Overall low awareness of the Omicron variant infection contributed to high transmission rates and rapid spread of SARS-CoV-2 in communities.

Jake Nichols, PharmD, CEO, president, and co-founder of Renovo Health, discusses his experience with drug diversion and addiction.

Narcissistic leaders have a negative impact on the culture of their organization as their conduct and management style induces fear.

The announcement marks the first protein-based COVID-19 vaccine authorized in the United States for this patient population.

The regulatory submission includes data from the MOMENTUM phase 3 clinical trial that met all primary and key second efficacy end points.

University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.

The American Heart Association includes 6 conditions and indicates that men’s and women’s experiences may differ.

Zerbaxa is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor.

Treatment with empagliflozin also found to improve cardiac geometry, myocardial mechano-energetic efficiency, and cardiac function.

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.

Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.

Investigators reported that people who frequently naps may have an increased risk of high blood pressure and ischemic stroke by 12% compared to people who do not nap.

Investigators find that establishing immunity in the mucosal areas establishes a frontline defense against these diseases.

The drug also meets the key secondary endpoint of improved overall survival for treatment for individuals with HER2 positive unresectable and/or metastatic breast cancer.

Ganciclovir injection is a nucleoside analogue cytomegalovirus DNA polymerase inhibitor.

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Rajul A. Patel, PharmD, PhD, director of the Medicare Part D Outreach Clinics at the University of the Pacific in Stockton, California, discusses his work providing drug savings advice to Medicare beneficiaries in diverse communities.

Investigators from University of Texas Health Science Center at Houston analyze data from individuals aged 5 to 18 years enrolled in the Texas CARES survey.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

Analysis looks at those with arthritis, chronic pain, headaches, lower back pain, and neuropathic pain between 2012 and 2019.